116 related articles for article (PubMed ID: 35902228)
1. Thalamic atrophy measured by artificial intelligence in a multicentre clinical routine real-word study is associated with disability progression.
Zivadinov R; Bergsland N; Jakimovski D; Weinstock-Guttman B; Benedict RHB; Riolo J; Silva D; Dwyer MG;
J Neurol Neurosurg Psychiatry; 2022 Jul; ():. PubMed ID: 35902228
[TBL] [Abstract][Full Text] [Related]
2. DeepGRAI (Deep Gray Rating via Artificial Intelligence): Fast, feasible, and clinically relevant thalamic atrophy measurement on clinical quality T2-FLAIR MRI in multiple sclerosis.
Dwyer M; Lyman C; Ferrari H; Bergsland N; Fuchs TA; Jakimovski D; Schweser F; Weinstock-Guttmann B; Benedict RHB; Riolo J; Silva D; Zivadinov R
Neuroimage Clin; 2021; 30():102652. PubMed ID: 33872992
[TBL] [Abstract][Full Text] [Related]
3. Therapy effect on AI-derived thalamic atrophy using clinical routine MRI protocol: A longitudinal, multi-center, propensity-matched multiple sclerosis study.
Jakimovski D; Silva D; Niels Bergsland ; Dwyer MG; Weinstock-Guttman B; Benedict RH; Riolo J; Zivadinov R;
Mult Scler Relat Disord; 2023 Jun; 74():104708. PubMed ID: 37084495
[TBL] [Abstract][Full Text] [Related]
4. Thalamic atrophy and dysconnectivity are associated with cognitive impairment in a multi-center, clinical routine, real-word study of people with relapsing-remitting multiple sclerosis.
Zivadinov R; Bergsland N; Jakimovski D; Weinstock-Guttman B; Lorefice L; Schoonheim MM; Morrow SA; Ann Picone M; Pardo G; Zarif M; Gudesblatt M; Nicholas JA; Smith A; Hunter S; Newman S; AbdelRazek MA; Hoti I; Riolo J; Silva D; Fuchs TA; Dwyer MG; Hb Benedict R
Neuroimage Clin; 2024; 42():103609. PubMed ID: 38718640
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS.
Zivadinov R; Bergsland N; Korn JR; Dwyer MG; Khan N; Medin J; Price JC; Weinstock-Guttman B; Silva D;
AJNR Am J Neuroradiol; 2018 Feb; 39(2):289-295. PubMed ID: 29170269
[TBL] [Abstract][Full Text] [Related]
6. Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study.
Barnett M; Bergsland N; Weinstock-Guttman B; Butzkueven H; Kalincik T; Desmond P; Gaillard F; van Pesch V; Ozakbas S; Rojas JI; Boz C; Altintas A; Wang C; Dwyer MG; Yang S; Jakimovski D; Kyle K; Ramasamy DP; Zivadinov R
Neuroimage Clin; 2021; 32():102802. PubMed ID: 34469848
[TBL] [Abstract][Full Text] [Related]
7. Clinical feasibility of longitudinal lateral ventricular volume measurements on T2-FLAIR across MRI scanner changes.
Jakimovski D; Zivadinov R; Bergsland N; Ramasamy DP; Hagemeier J; Genovese AV; Hojnacki D; Weinstock-Guttman B; Dwyer MG
Neuroimage Clin; 2021; 29():102554. PubMed ID: 33472143
[TBL] [Abstract][Full Text] [Related]
8. Thalamic-hippocampal-prefrontal disruption in relapsing-remitting multiple sclerosis.
Kern KC; Gold SM; Lee B; Montag M; Horsfall J; O'Connor MF; Sicotte NL
Neuroimage Clin; 2015; 8():440-7. PubMed ID: 26106524
[TBL] [Abstract][Full Text] [Related]
9. A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis.
Tavazzi E; Bergsland N; Kuhle J; Jakimovski D; Ramanathan M; Maceski AM; Tomic D; Hagemeier J; Kropshofer H; Leppert D; Dwyer MG; Weinstock-Guttman B; Benedict RHB; Zivadinov R
J Neurol; 2020 Mar; 267(3):802-811. PubMed ID: 31768628
[TBL] [Abstract][Full Text] [Related]
10. Subcortical brain segmentation of two dimensional T1-weighted data sets with FMRIB's Integrated Registration and Segmentation Tool (FIRST).
Amann M; Andělová M; Pfister A; Mueller-Lenke N; Traud S; Reinhardt J; Magon S; Bendfeldt K; Kappos L; Radue EW; Stippich C; Sprenger T
Neuroimage Clin; 2015; 7():43-52. PubMed ID: 25610766
[TBL] [Abstract][Full Text] [Related]
11. Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis.
Dwyer MG; Silva D; Bergsland N; Horakova D; Ramasamy D; Durfee J; Vaneckova M; Havrdova E; Zivadinov R
Neuroimage Clin; 2017; 15():769-779. PubMed ID: 28706852
[TBL] [Abstract][Full Text] [Related]
12. FLAIR-only joint volumetric analysis of brain lesions and atrophy in clinically isolated syndrome (CIS) suggestive of multiple sclerosis.
Goodkin O; Prados F; Vos SB; Pemberton H; Collorone S; Hagens MHJ; Cardoso MJ; Yousry TA; Thornton JS; Sudre CH; Barkhof F;
Neuroimage Clin; 2021; 29():102542. PubMed ID: 33418171
[TBL] [Abstract][Full Text] [Related]
13. Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis.
Genovese AV; Hagemeier J; Bergsland N; Jakimovski D; Dwyer MG; Ramasamy DP; Lizarraga AA; Hojnacki D; Kolb C; Weinstock-Guttman B; Zivadinov R
Radiology; 2019 Nov; 293(2):424-433. PubMed ID: 31549947
[TBL] [Abstract][Full Text] [Related]
14. Thalamic atrophy correlates with dysfunctional impulsivity in multiple sclerosis.
Joly H; Capet N; Mondot L; Cohen M; Suply C; Bresch S; Lebrun-Frenay C
Mult Scler Relat Disord; 2020 Sep; 44():102374. PubMed ID: 32652509
[TBL] [Abstract][Full Text] [Related]
15. Clinical Relevance of Multiparametric MRI Assessment of Cervical Cord Damage in Multiple Sclerosis.
Bonacchi R; Pagani E; Meani A; Cacciaguerra L; Preziosa P; De Meo E; Filippi M; Rocca MA
Radiology; 2020 Sep; 296(3):605-615. PubMed ID: 32573387
[TBL] [Abstract][Full Text] [Related]
16. Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis.
Hofstetter L; Naegelin Y; Filli L; Kuster P; Traud S; Smieskova R; Mueller-Lenke N; Kappos L; Gass A; Sprenger T; Penner IK; Nichols TE; Vrenken H; Barkhof F; Polman C; Radue EW; Borgwardt SJ; Bendfeldt K
Mult Scler; 2014 Feb; 20(2):202-13. PubMed ID: 23804554
[TBL] [Abstract][Full Text] [Related]
17. Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis.
Magon S; Tsagkas C; Gaetano L; Patel R; Naegelin Y; Amann M; Parmar K; Papadopoulou A; Wuerfel J; Stippich C; Kappos L; Chakravarty MM; Sprenger T
J Neurol; 2020 May; 267(5):1536-1546. PubMed ID: 32040710
[TBL] [Abstract][Full Text] [Related]
18. Deep gray matter changes in relapsing-remitting multiple sclerosis detected by multi-parametric, high-resolution magnetic resonance imaging (MRI).
Al-Radaideh A; Athamneh I; Alabadi H; Hbahbih M
Eur Radiol; 2021 Feb; 31(2):706-715. PubMed ID: 32851443
[TBL] [Abstract][Full Text] [Related]
19. Quantifying disease pathology and predicting disease progression in multiple sclerosis with only clinical routine T2-FLAIR MRI.
Fuchs TA; Dwyer MG; Jakimovski D; Bergsland N; Ramasamy DP; Weinstock-Guttman B; Hb Benedict R; Zivadinov R
Neuroimage Clin; 2021; 31():102705. PubMed ID: 34091352
[TBL] [Abstract][Full Text] [Related]
20. Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.
Gaetano L; Häring DA; Radue EW; Mueller-Lenke N; Thakur A; Tomic D; Kappos L; Sprenger T
Neurology; 2018 Apr; 90(15):e1324-e1332. PubMed ID: 29540589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
